Sumitomo Dainippon, Roivant to create £2.4bn biopharma alliance
Under the deal, Sumitomo Dainippon Pharma will have the option to acquire up to six more Vants of Roivant. Additionally, the Japanese firm will take an equity stake
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).